Ceribell
Valuation each multiple against its own 5-year range
Vs. peers Medical Devices
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Ceribell (CBLL) | 906.87M | -13.43 | 7.07 | 0.00% |
| Abbott Laboratories (ABT) | 172.35B | 32.23 | 3.37 | 2.45% |
| Medtronic (MDT) | 113.18B | 21.79 | 2.25 | 3.22% |
| Stryker Corp (SYK) | 106.38B | 28.74 | 4.43 | 1.25% |
| Boston Scientific (BSX) | 61.93B | 17.30 | 2.48 | 0.00% |
| Edwards Lifesciences (EW) | 49.12B | 49.54 | 4.63 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 43.3% below Morningstar's fair value estimate.
Fair value
CeriBell Inc is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 31% discount to our quantitative fair value estimate of $33.86 per share; however, caution is warranted due to this estimate's very high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.
The company's valuation metrics bolster our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's price to cash ratio of 7.0 ranks in the bottom 50% globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be cheap.
The company's balance sheet is an additional encouraging factor. Low leverage mitigates financial risk, potentially boosting a firm's value. The firm's current ratio of 9.2, a core component of leverage, lies in the top 10% compared with global peers. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which further promotes our favorable price/fair value ratio.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.
Economic moat
With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-10-09 19:30:04 · For reference only, not investment advice and not tailored to your situation.
Ceribell discussion 0 comments